Medical cannabis use in Thailand after its legalization a respondent-driven sample survey.
Many countries now allow the consumption of cannabis or cannabinoids for medical purposes with varying approaches concerning products allowed and the regulatory frameworks prevailing their endowment. On 18 February 2019 Thailand passed legislation allowing the use of cannabis for medical purposes. This study aimed to examine patterns and purposes for consumption of medical cannabis, and consumers perceptions and opinions towards benefits and harms of cannabis and related policies in 2019-2020. A cross-sectional study using a respondent-driven sampling (RDS) method was conducted in four sites across Thailand. Participants were 485 adults aged 18 years and over, living in the study region, who had used cannabis for medical purposes within the past 12 months. Face-to-face interviews using a structured questionnaire were used to collect data on (1) demographic characteristics, (2) pattern of consumption, (3) source of information and perception of benefits and harms of medical cannabis, and (4) opinion towards cannabis policies. Data were analyzed using RDS Analyst and presented as percentage and mean with 95% confidence interval (CI). Most participants (84.7%, 95% CI 78.9-90.5) used an oral form of crude oil extract while 9.2% (95% CI 4.1-14.2) used the raw form. The most common uses were for treatment of cancers (23.3%, 95% CI 16.1-30.4), neuropsychiatric symptoms (22.8%, 95% CI 17.5-28.0), and musculoskeletal pains (21.6%, 95% CI 16.7-26.6). Illegal sources such as underground traders (54.5%, 95% CI 40.8-68.3), friends and relatives (12.2%, 95% CI 6.2-18.3), not-for-profit provider groups (5.2%, 95% CI 0.5-10.9), and clandestine growers or producers (2.9%, 95% CI 0.6-5.3) were the main suppliers. Most (>80%) perceived cannabis could treat cancers, chronic pains, insomnia, Parkinsons disease and generalized anxiety disorder. Less than half perceived that cannabis could cause adverse conditions Our study reports the experiences of consumers of medical cannabis in the first year after its legalization in Thailand. Consumers reported various patterns and indications of consumption that were not supported by scientific evidence, but had positive perception of the results of consumption. These findings highlight ongoing policy challenges for Thailand and can be a lesson to be learned for other countries in the region.